<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Biol Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Biol Med</journal-id><journal-id journal-id-type="publisher-id">CBM</journal-id><journal-title-group><journal-title>Cancer Biology &#x00026; Medicine</journal-title></journal-title-group><issn pub-type="ppub">2095-3941</issn><publisher><publisher-name>Chinese Anti-Cancer Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25859412</article-id><article-id pub-id-type="pmc">4383844</article-id><article-id pub-id-type="publisher-id">cbm-12-01-053</article-id><article-id pub-id-type="doi">10.7497/j.issn.2095-3941.2015.0005</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Difference between papillary and follicular thyroid carcinoma outcomes: an experience from Egyptian institution</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aboelnaga</surname><given-names>Engy M.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ahmed</surname><given-names>Rehab Allah</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><aff><target id="aff1" target-type="aff"><sup>1</sup></target>Clinical Oncology and Nuclear Medicine Department, <target id="aff2" target-type="aff"><sup>2</sup></target>Pathology Department, Faculty of Medicine, Mansoura University, Mansoura 35511, <country>Egypt</country></aff></contrib-group><author-notes><fn id="afn1"><p>Correspondence to: Engy M. Aboelnaga</p></fn><fn id="afn2"><p>E-mail: <email xlink:href="engyms2007@gmail.com">engyms2007@gmail.com</email></p></fn></author-notes><pub-date pub-type="epub-ppub"><month>3</month><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>3</month><year>2015</year></pub-date><volume>12</volume><issue>1</issue><fpage>53</fpage><lpage>59</lpage><history><date date-type="received"><day>14</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>2015 Cancer Biology &#x00026; Medicine</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Cancer Biology &#x00026; Medicine</copyright-holder><license license-type="open-access"><license-p>This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link></license-p></license></permissions><abstract><sec><title>Objective</title><p>Differentiated thyroid carcinomas (DTCs) are classified into papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC). DTCs are analyzed as a single group in clinical studies that investigated the prognostic factors and prognosis of these malignancies. However, the biological behaviors of these carcinomas significantly differ. In the present study, we aimed to detect differences in the outcomes between PTC and FTC in Mansoura University Hospital in Egypt.</p></sec><sec><title>Methods</title><p>A total of 558 patients with histologically proven thyroid carcinomas from January 2003 to December 2012 were retrospectively enrolled. The clinical and pathological data of patients were reviewed.</p></sec><sec><title>Results</title><p>Large primary tumor size, lymph node involvement, extrathyroid extension, and distant metastasis were significant poor prognostic factors for overall survival (OS) in old PTC patients. Cox hazard analysis showed that the patient&#x02019;s age, extra thyroid extension, and distant metastasis were the only independent prognostic factors. In FTC patients, only the distant metastasis and degree of tumor invasion were significant poor prognostic factors in OS univariate analysis. However, these factors were nonsignificant in multivariate analysis. The 10-year OS rates were 97% and 89% for PTC and FTC, respectively (<italic>P</italic>=0.003). The 10-year disease-free survival (DFS) rates were 77.2% in PTC <italic>vs</italic>. 65% in FTC (<italic>P</italic>=0.179).</p></sec><sec><title>Conclusion</title><p>The significant prognostic factors vary between the two types of DTCs. Therefore, PTC and FTC patients need to be analyzed and reported independently. PTC survival is widely and significantly affected by age, extrathyroid extension, and distant metastasis. By contrast, these factors were nonsignificant in FTC, which showed poorer survival than PTC.</p></sec></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS </title><kwd>Thyroid cancer</kwd><kwd>differentiated thyroid</kwd><kwd>papillary</kwd><kwd>follicular</kwd><kwd>Egypt</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Differentiated thyroid carcinoma (DTC) originates from epithelial follicular cell and considered as a major form of thyroid carcinoma. DTC includes two histological types, namely, papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC)<xref rid="r1" ref-type="bibr"><sup>1</sup></xref>.</p><p>DTC is mostly indolent and a clinically nonsignificant disease that is found incidentally with good prognosis in most cases and a high 10-year survival rate (90%-95%)<xref rid="r2" ref-type="bibr"><sup>2</sup></xref>.</p><p>A thyroid nodule is the first symptom of thyroid cancer and of particular concern when found in patients younger than 20 years old, with greater potential for malignant presentation in such cases. Pain in the anterior region of the neck and changes in voice may occur as late symptoms because of the involvement of the recurrent laryngeal nerve<xref rid="r3" ref-type="bibr"><sup>3</sup></xref>.</p><p>Approximately 80%-85% of all thyroid malignancies are PTCs. In addition to the classic form of PTCs, several morphological variants, usually classified as biologically aggressive, have been identified: diffuse sclerosing, tall cell, columnar cell, solid/trabecular, and insular variants<xref rid="r4" ref-type="bibr"><sup>4</sup></xref>. The aggressive behavior of PTC is attributed to its invasion into extrathyroidal tissues and extensive vascular invasion<xref rid="r5" ref-type="bibr"><sup>5</sup></xref>. However, recent studies have shown that some of these variants (sclerosing and tall cell) are not related to poor outcome <italic>per se</italic>, but rather tumor prognosis is dependent on the presence of aggressive features, such as extracapsular and vascular invasion, larger tumor size, and the presence of distant metastasis (DM)<xref rid="r6" ref-type="bibr"><sup>6</sup></xref><sup>,</sup><xref rid="r7" ref-type="bibr"><sup>7</sup></xref>. FTC is the second most frequent subtype and accounts for approximately 10%-15% of all thyroid cancers. H&#x000fc;rthle cell thyroid carcinoma is a variant of FTC that accounts for 3% of thyroid malignancies and is characterized by less sensitivity to iodine therapy<xref rid="r8" ref-type="bibr"><sup>8</sup></xref><sup>,</sup><xref rid="r9" ref-type="bibr"><sup>9</sup></xref>.</p><p>DTCs are analyzed as a single group in clinical studies that investigate the prognostic factors and prognosis of patients. However, the biological behaviors of the two types of DTC significantly vary. PTC metastasizes frequently to the regional lymph nodes and may show a high incidence of significant extrathyroid extension to adjacent organs. By contrast, FTC more frequently metastasizes to more distant organs, such as the lung, bone, and brain, than PTC<xref rid="r10" ref-type="bibr"><sup>10</sup></xref>.</p><p>PTC and FTC are often treated similarly despite their numerous biological differences. The most effective management of thyroid cancers is the surgical removal of the thyroid gland (thyroidectomy), followed by radioactive iodine (RAI) ablation and thyroid replacement therapy for TSH suppression. Chemotherapy or radiotherapy has a limited role only in cases with DM or advanced cancer stage<xref rid="r11" ref-type="bibr"><sup>11</sup></xref>.</p><p>Unlike most cancers, recurrence of DTC does not necessarily correlate with increased risk of mortality. This phenomenon is particularly demonstrated in young patients who have higher rates of local recurrence, but have low mortality risk. Several clinical features enable initial risk stratification, including patient age, size of the primary tumor, histology, gross extra-thyroidal extension, completeness of resection, involvement of the cervical lymph nodes, or DM<xref rid="r12" ref-type="bibr"><sup>12</sup></xref>.</p><p>In the present study, we aimed to distinguish the outcomes of prognosis between PTC and FTC in a single institution (Mansoura University Hospital in Egypt).</p></sec><sec sec-type="methods"><title>Patients and methods</title><sec><title>Patient data</title><p>A total of 558 patients, with histologically proven thyroid carcinoma from January 2003 to December 2012, were retrospectively included in this study. This study was approved by the ethics committee at Mansoura University Hospital.</p><p>The data were collected from the archives of patients in the clinical oncology and nuclear medicine departments, as well as those in the pathology department. The data included the general characteristics of patients and tumor: age, sex, primary tumor size, the number of lymph node metastasis, multifocality of the primary lesion, extrathyroid extension, subtypes of papillary and follicular thyroid carcinoma, TNM stage based on TNM staging of the American Joint Committee on Cancer, and the development of DM<xref rid="r13" ref-type="bibr"><sup>13</sup></xref>. Extrathyroid extension was defined according to the TNM criteria as follows: any tumor with minimal extrathyroid extension as extension to sternothyroid muscle or perithyroid soft tissues (PT<sub>3</sub>); tumor of any size that extends beyond the thyroid capsule and invades subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve (PT<sub>4a</sub>); or tumor that invades the prevertebral fascia or encases carotid artery (PT<sub>4b</sub>). Patients with focal poorly differentiated carcinoma, focal undifferentiated carcinoma, or DM at the time of diagnosis were excluded from this study.</p><p>Treatment modalities, which included the type of surgical resection and either hemi-thyroidectomy, near, or subtotal thyroidectomy with lymph node dissection, were performed in positive lymph node cases. Redo surgery (completion thyroidectomy) was performed in cases with postoperative large residual tumor. Postoperative treatment, which included radioiodine ablation <sup>131</sup>I (80-120 mCi) in patients who underwent at least a near-total thyroidectomy and thyroxine suppression therapy, was also recorded. Chemotherapy was used in some cases of metastatic or non-resectable DTC, and radiotherapy was used as palliative treatment for metastatic or unresectable cases.</p><p>Follow-up data of patients were retrieved from the archive of the Clinical Oncology and Nuclear Medicine Department, and the survival data, including the overall survival (OS) and disease-free survival (DFS), were collected.</p><p>DFS was calculated from the date of surgery until the date of recurrence (either local or distant), and OS was calculated from the date of diagnosis until the date of death of the patient (regardless of the cause of death).</p></sec><sec><title>Statistical analysis</title><p>Data were analyzed using Statistical Package for Social Sciences Version 16 (SPSS Inc., Chicago, IL, USA). Qualitative data were presented as number and percentage. Survival curves were estimated by the Kaplan-Meier method with log rank test to assess significance. Multivariate Cox proportional hazard regression models were used to evaluate any independent prognostic effect of the variables with 95% confidence interval (CI). A <italic>P</italic>-value of &#x0003c;0.05 was considered significant.</p></sec></sec><sec sec-type="results"><title>Results</title><p>In the present retrospective study, 558 patients were enrolled, and their data were analyzed with median follow-up period of 52 months (range: 12-120 months). A total of 477 patients (85.5%) were diagnosed with PTC, whereas FTC was found in 81 (14.5%) patients.</p><p>Other patients&#x02019; characteristics are shown in <xref ref-type="table" rid="t1"><bold>Table 1</bold></xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Clinicopathological features of all thyroid carcinoma patients</title></caption><table frame="hsides" rules="groups"><col width="48.63%" span="1"/><col width="12.12%" span="1"/><col width="12.08%" span="1"/><col width="1.61%" span="1"/><col width="13.48%" span="1"/><col width="12.08%" span="1"/><thead><tr><th rowspan="2" valign="middle" align="left" scope="col" style="border-bottom: solid 1.0pt" colspan="1">Characteristics</th><th valign="middle" colspan="2" align="center" scope="colgroup" style="border-bottom: solid 1.0pt" rowspan="1">PTC (<italic>n</italic>=477)<hr/></th><th rowspan="2" valign="middle" align="left" scope="col" style="border-bottom: solid 1.0pt" colspan="1"/><th valign="middle" colspan="2" align="center" scope="colgroup" style="border-bottom: solid 1.0pt" rowspan="1">FTC (<italic>n</italic>=81)<hr/></th></tr><tr><th valign="middle" colspan="1" align="center" scope="colgroup" style="border-top: solid 1.0pt" rowspan="1"><italic>n</italic></th><th valign="middle" align="center" scope="col" style="border-top: solid 1.0pt" rowspan="1" colspan="1">%</th><th valign="middle" colspan="1" align="center" scope="colgroup" style="border-top: solid 1.0pt" rowspan="1"><italic>n</italic></th><th valign="middle" align="center" scope="col" style="border-top: solid 1.0pt" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gender</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td valign="middle" align="center" rowspan="1" colspan="1">145</td><td valign="middle" align="center" rowspan="1" colspan="1">30.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">23</td><td valign="middle" align="center" rowspan="1" colspan="1">28.4</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td valign="middle" align="center" rowspan="1" colspan="1">332</td><td valign="middle" align="center" rowspan="1" colspan="1">69.6</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">58</td><td valign="middle" align="center" rowspan="1" colspan="1">71.6</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male: female ratio</td><td valign="middle" align="center" rowspan="1" colspan="1">01:02.2</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">01:02.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Patients&#x02019; age (years)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;45</td><td valign="middle" align="center" rowspan="1" colspan="1">284</td><td valign="middle" align="center" rowspan="1" colspan="1">59.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">37</td><td valign="middle" align="center" rowspan="1" colspan="1">45.7</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265;45</td><td valign="middle" align="center" rowspan="1" colspan="1">193</td><td valign="middle" align="center" rowspan="1" colspan="1">40.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">44</td><td valign="middle" align="center" rowspan="1" colspan="1">54.3</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Median in years (range)</td><td valign="middle" align="center" rowspan="1" colspan="1">40 (8-71)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">40 (21-72)</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Primary tumor size (cm)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264;1</td><td valign="middle" align="center" rowspan="1" colspan="1">57</td><td valign="middle" align="center" rowspan="1" colspan="1">11.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">2</td><td valign="middle" align="center" rowspan="1" colspan="1">2.5</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;1 and &#x02264;2</td><td valign="middle" align="center" rowspan="1" colspan="1">110</td><td valign="middle" align="center" rowspan="1" colspan="1">23.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">7</td><td valign="middle" align="center" rowspan="1" colspan="1">8.6</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;2 and &#x02264;4</td><td valign="middle" align="center" rowspan="1" colspan="1">223</td><td valign="middle" align="center" rowspan="1" colspan="1">46.8</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">37</td><td valign="middle" align="center" rowspan="1" colspan="1">45.7</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;4</td><td valign="middle" align="center" rowspan="1" colspan="1">87</td><td valign="middle" align="center" rowspan="1" colspan="1">18.2</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">35</td><td valign="middle" align="center" rowspan="1" colspan="1">43.2</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Lymph node status</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N<sub>0</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">302</td><td valign="middle" align="center" rowspan="1" colspan="1">63.3</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">75</td><td valign="middle" align="center" rowspan="1" colspan="1">92.6</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N<sub>1</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">175</td><td valign="middle" align="center" rowspan="1" colspan="1">36.7</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">6</td><td valign="middle" align="center" rowspan="1" colspan="1">7.4</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Development of DM</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td valign="middle" align="center" rowspan="1" colspan="1">456</td><td valign="middle" align="center" rowspan="1" colspan="1">95.6</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">59</td><td valign="middle" align="center" rowspan="1" colspan="1">72.8</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td valign="middle" align="center" rowspan="1" colspan="1">21</td><td valign="middle" align="center" rowspan="1" colspan="1">4.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">22</td><td valign="middle" align="center" rowspan="1" colspan="1">27.2</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Extrathyroid extension</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td valign="middle" align="center" rowspan="1" colspan="1">444</td><td valign="middle" align="center" rowspan="1" colspan="1">93.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">77</td><td valign="middle" align="center" rowspan="1" colspan="1">95.1</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Probable</td><td valign="middle" align="center" rowspan="1" colspan="1">33</td><td valign="middle" align="center" rowspan="1" colspan="1">6.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">4</td><td valign="middle" align="center" rowspan="1" colspan="1">4.9</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Multifocality</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td valign="middle" align="center" rowspan="1" colspan="1">440</td><td valign="middle" align="center" rowspan="1" colspan="1">92.2</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">78</td><td valign="middle" align="center" rowspan="1" colspan="1">96.3</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">37</td><td valign="middle" align="center" rowspan="1" colspan="1">7.8</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">3</td><td valign="middle" align="center" rowspan="1" colspan="1">3.7</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Subtypes of PTC/FTC</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Classic/classic</td><td valign="middle" align="center" rowspan="1" colspan="1">331</td><td valign="middle" align="center" rowspan="1" colspan="1">69.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">58</td><td valign="middle" align="center" rowspan="1" colspan="1">71.6</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Follicular/H&#x000fc;rthle cell carcinoma</td><td valign="middle" align="center" rowspan="1" colspan="1">133</td><td valign="middle" align="center" rowspan="1" colspan="1">27.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">23</td><td valign="middle" align="center" rowspan="1" colspan="1">28.4</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Others*</td><td valign="middle" align="center" rowspan="1" colspan="1">13</td><td valign="middle" align="center" rowspan="1" colspan="1">2.7</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" scope="col" rowspan="1" colspan="1">Degree of invasion</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Minimally invasive</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">48</td><td valign="middle" align="center" rowspan="1" colspan="1">59.3</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Widely invasive</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">33</td><td valign="middle" align="center" rowspan="1" colspan="1">40.7</td></tr></tbody></table><table-wrap-foot><p>*, Including encapsulated tall and columnar cell variants. DM, distant metastasis; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma.</p></table-wrap-foot></table-wrap><sec><title>Prognostic features of PTC</title><p>Our results showed that old age, large primary tumor size, lymph node stage, extrathyroid extension, and DM were significant poor prognostic factors for PTC on the univariate analysis of OS (<xref ref-type="table" rid="t2"><bold>Table 2</bold></xref>). Multivariate COX hazard analysis showed that patient age (HR =5.94; 95% CI, 1.237-28.650; <italic>P</italic>=0.026), extrathyroid extension (HR =3.527; 95% CI, 1.070-11.626; <italic>P</italic>=0.038), and DM (HR =12.968; 95% CI, 3.924-42.854; <italic>P</italic>&#x0003c;0.001) were the only independent prognostic factors of OS. Results from the univariate analysis of the various prognostic factors in the PTC patients&#x02019; series in relation to DFS using log rank test are summarized in <xref ref-type="table" rid="t2"><bold>Table 2</bold></xref>. Our results showed that male gender, old age, large primary tumor size, lymph node metastasis, extrathyroid extension, and multifocality were significant poor prognostic factors, but the multivariate COX hazard analysis showed that tumor size (HR =3.972; 95% CI, 1.237-15.650; <italic>P</italic>=0.023) and lymph node stage (HR =5.434; 95% CI, 1.245-26.530; <italic>P</italic>=0.014) were the only independent prognostic factors (<xref ref-type="table" rid="t3"><bold>Table 3</bold></xref>).</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Prognostic variables in PTC in relation to OS and DFS</title></caption><table frame="hsides" rules="groups"><col width="32.4%" span="1"/><col width="17.71%" span="1"/><col width="17.7%" span="1"/><col width="16.09%" span="1"/><col width="16.1%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Characteristics</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">OS (%)</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic></th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">DFS (%)</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Gender</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.668</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.001</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td valign="middle" align="center" rowspan="1" colspan="1">96.7</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">67.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td valign="middle" align="center" rowspan="1" colspan="1">97.7</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">82.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Patients&#x02019; age (years)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;45</td><td valign="middle" align="center" rowspan="1" colspan="1">98.8</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">85.8</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265;45</td><td valign="middle" align="center" rowspan="1" colspan="1">94.2</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">66.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Primary tumor size (cm)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.002</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264;1</td><td valign="middle" align="center" rowspan="1" colspan="1">100</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">91.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;1 and &#x02264;2</td><td valign="middle" align="center" rowspan="1" colspan="1">100</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">89.2</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;2 and &#x02264;4</td><td valign="middle" align="center" rowspan="1" colspan="1">96.8</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">79.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;4</td><td valign="middle" align="center" rowspan="1" colspan="1">90.3</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">40.3</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Lymph node status</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N<sub>0</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">100</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">94.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N<sub>1</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">91.8</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">49.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Development of DM</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td valign="middle" align="center" rowspan="1" colspan="1">98.6</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td valign="middle" align="center" rowspan="1" colspan="1">63.2</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Extrathyroid extension</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td valign="middle" align="center" rowspan="1" colspan="1">98</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">82</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Probable</td><td valign="middle" align="center" rowspan="1" colspan="1">84.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">28</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Multifocality</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.94</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td valign="middle" align="center" rowspan="1" colspan="1">97</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">79.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">94.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">55.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Subtypes</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.15</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.642</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Classic</td><td valign="middle" align="center" rowspan="1" colspan="1">98</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">98</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Follicular</td><td valign="middle" align="center" rowspan="1" colspan="1">94.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">94.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Others*</td><td valign="middle" align="center" rowspan="1" colspan="1">100</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">100</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>*, Including encapsulated tall and columnar cell variants. PTC, papillary thyroid carcinoma; OS, overall survival; DFS, disease-free survival; DM, distant metastasis.</p></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><title>COX proportional hazard analysis of the predictors of DFS in the PTC series</title></caption><table frame="hsides" rules="groups"><col width="34.48%" span="1"/><col width="16.33%" span="1"/><col width="16.95%" span="1"/><col width="15.93%" span="1"/><col width="16.31%" span="1"/><thead><tr><th rowspan="2" valign="middle" align="left" scope="col" style="border-bottom: solid 1.0pt" colspan="1">Variable</th><th rowspan="2" valign="middle" align="center" scope="col" style="border-bottom: solid 1.0pt" colspan="1"><italic>P</italic></th><th rowspan="2" valign="middle" align="center" scope="col" style="border-bottom: solid 1.0pt" colspan="1">HR</th><th valign="middle" colspan="2" align="center" scope="colgroup" style="border-bottom: solid 1.0pt" rowspan="1">95% CI<hr/></th></tr><tr><th valign="middle" colspan="1" align="center" scope="colgroup" style="border-top: solid 1.0pt" rowspan="1">Lower</th><th valign="middle" align="center" scope="col" style="border-top: solid 1.0pt" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Gender</td><td valign="middle" align="center" rowspan="1" colspan="1">0.356</td><td valign="middle" align="center" rowspan="1" colspan="1">0.607</td><td valign="middle" align="center" rowspan="1" colspan="1">0.21</td><td valign="middle" align="center" rowspan="1" colspan="1">1.752</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Patients&#x02019; age</td><td valign="middle" align="center" rowspan="1" colspan="1">0.791</td><td valign="middle" align="center" rowspan="1" colspan="1">0.884</td><td valign="middle" align="center" rowspan="1" colspan="1">0.354</td><td valign="middle" align="center" rowspan="1" colspan="1">2.204</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Tumor size</td><td valign="middle" align="center" rowspan="1" colspan="1">0.033</td><td valign="middle" align="center" rowspan="1" colspan="1">1.892</td><td valign="middle" align="center" rowspan="1" colspan="1">1.051</td><td valign="middle" align="center" rowspan="1" colspan="1">3.404</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">LN stage</td><td valign="middle" align="center" rowspan="1" colspan="1">0.002</td><td valign="middle" align="center" rowspan="1" colspan="1">4.975</td><td valign="middle" align="center" rowspan="1" colspan="1">1.845</td><td valign="middle" align="center" rowspan="1" colspan="1">13.411</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Multifocality</td><td valign="middle" align="center" rowspan="1" colspan="1">0.644</td><td valign="middle" align="center" rowspan="1" colspan="1">1.313</td><td valign="middle" align="center" rowspan="1" colspan="1">0.414</td><td valign="middle" align="center" rowspan="1" colspan="1">4.159</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Extrathyroid extension</td><td valign="middle" align="center" rowspan="1" colspan="1">0.075</td><td valign="middle" align="center" rowspan="1" colspan="1">2.72</td><td valign="middle" align="center" rowspan="1" colspan="1">0.904</td><td valign="middle" align="center" rowspan="1" colspan="1">8.18</td></tr></tbody></table><table-wrap-foot><p>PTC, papillary thyroid carcinoma; DFS, disease-free survival.</p></table-wrap-foot></table-wrap><p>We studied the differences in survival between the various types of PTC in terms of the OS and DFS, and no significant relationship was found [OS (LR =3.788, <italic>P</italic>=0.150) or DFS (LR =0.798, <italic>P</italic>=0.671)].</p></sec><sec><title>Prognostic features of FTC</title><p>We found that the only factors that significantly affected the OS of FTC patients were DM and degree of tumor invasion (<xref ref-type="table" rid="t4"><bold>Table 4</bold></xref>). However, none of these remained independent in the multivariate analysis. The factors that affected the DFS of FTC on univariate analysis are summarized in <xref ref-type="table" rid="t4"><bold>Table 4</bold></xref>. The results showed that tumor size, extrathyroid extension, and degree of tumor invasion were the only significant poor prognostic factors in FTC patients. Only extrathyroid extension (HR =10.956; 95% CI, 2.724-39.864; <italic>P</italic>&#x0003c;0.001) and degree of tumor invasion (HR =5.547; 95% CI, 1.684-27.754; <italic>P</italic>=0.025) remained independent in the multivariate analysis in our patients&#x02019; series (<xref ref-type="table" rid="t5"><bold>Table 5</bold></xref>). However, the various types of FTC did not exhibit any significant effect on OS (<italic>P</italic>=0.097) or DFS (<italic>P</italic>=0.410).</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Prognostic variables in FTC in relation to OS and DFS</title></caption><table frame="hsides" rules="groups"><col width="35.84%" span="1"/><col width="17.11%" span="1"/><col width="15.48%" span="1"/><col width="15.89%" span="1"/><col width="15.68%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Characteristics</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">OS (%)</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic></th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">DFS (%)</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Gender</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.822</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.675</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Male</td><td valign="middle" align="center" rowspan="1" colspan="1">88.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">57.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Female</td><td valign="middle" align="center" rowspan="1" colspan="1">90.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">67.3</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Patients&#x02019; age (years)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.253</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.102</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003c;45</td><td valign="middle" align="center" rowspan="1" colspan="1">94.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">73.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02265;45</td><td valign="middle" align="center" rowspan="1" colspan="1">84.6</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">56.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Primary tumor size (cm)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.432</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.017</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x02264;1</td><td valign="middle" align="center" rowspan="1" colspan="1">100</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">50</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;1 and &#x02264;2</td><td valign="middle" align="center" rowspan="1" colspan="1">80</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">80</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;2 and &#x02264;4</td><td valign="middle" align="center" rowspan="1" colspan="1">94.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">76.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x0003e;4</td><td valign="middle" align="center" rowspan="1" colspan="1">84.4</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">50</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Lymph node status</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.504</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.789</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N<sub>0</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">88.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">64.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;N<sub>1</sub></td><td valign="middle" align="center" rowspan="1" colspan="1">100</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">75</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Development of DM</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x02013;</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td valign="middle" align="center" rowspan="1" colspan="1">98.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Positive</td><td valign="middle" align="center" rowspan="1" colspan="1">66.7</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Extrathyroid extension</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.16</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td valign="middle" align="center" rowspan="1" colspan="1">90</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">67.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">66.7</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Multifocality</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.94</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.055</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No</td><td valign="middle" align="center" rowspan="1" colspan="1">97</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">47</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Yes</td><td valign="middle" align="center" rowspan="1" colspan="1">94.1</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Subtypes</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.097</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.41</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Classic</td><td valign="middle" align="center" rowspan="1" colspan="1">92.6</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">66.7</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;H&#x000fc;rthle cell carcinoma</td><td valign="middle" align="center" rowspan="1" colspan="1">78.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">57.9</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Degree of invasion</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">0.004</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Minimally invasive</td><td valign="middle" align="center" rowspan="1" colspan="1">97.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">82.5</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Widely invasive</td><td valign="middle" align="center" rowspan="1" colspan="1">78.6</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1">39.3</td><td valign="middle" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p>FTC, follicular thyroid carcinoma; OS, overall survival; DFS, disease-free survival; DM, distant metastasis.</p></table-wrap-foot></table-wrap><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><title>COX proportional hazard analysis of the predictors of DFS in the FTC series</title></caption><table frame="hsides" rules="groups"><col width="31.47%" span="1"/><col width="16.38%" span="1"/><col width="17.88%" span="1"/><col width="16.39%" span="1"/><col width="17.88%" span="1"/><thead><tr><th rowspan="2" valign="middle" align="left" scope="col" style="border-bottom: solid 1.0pt" colspan="1">Variable</th><th rowspan="2" valign="middle" align="center" scope="col" style="border-bottom: solid 1.0pt" colspan="1"><italic>P</italic></th><th rowspan="2" valign="middle" align="center" scope="col" style="border-bottom: solid 1.0pt" colspan="1">HR</th><th valign="middle" colspan="2" align="center" scope="colgroup" style="border-bottom: solid 1.0pt" rowspan="1">95% CI<hr/></th></tr><tr><th valign="middle" colspan="1" align="center" scope="colgroup" style="border-top: solid 1.0pt" rowspan="1">Lower</th><th valign="middle" align="center" scope="col" style="border-top: solid 1.0pt" rowspan="1" colspan="1">Upper</th></tr></thead><tbody><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Tumor size, cm</td><td valign="middle" align="center" rowspan="1" colspan="1">0.244</td><td valign="middle" align="center" rowspan="1" colspan="1">0.576</td><td valign="middle" align="center" rowspan="1" colspan="1">0.227</td><td valign="middle" align="center" rowspan="1" colspan="1">1.458</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Extrathyroid extension</td><td valign="middle" align="center" rowspan="1" colspan="1">0.021</td><td valign="middle" align="center" rowspan="1" colspan="1">4.937</td><td valign="middle" align="center" rowspan="1" colspan="1">1.279</td><td valign="middle" align="center" rowspan="1" colspan="1">19.057</td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Degree of invasion</td><td valign="middle" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td><td valign="middle" align="center" rowspan="1" colspan="1">13.118</td><td valign="middle" align="center" rowspan="1" colspan="1">3.364</td><td valign="middle" align="center" rowspan="1" colspan="1">51.144</td></tr></tbody></table><table-wrap-foot><p>DFS, disease-free survival; FTC, follicular thyroid carcinoma.</p></table-wrap-foot></table-wrap></sec><sec><title>Treatment</title><p>Total or near total thyroidectomy was performed in 97.1% of our patients. Hemithyroidectomy was performed in 2.9%, and redo surgery was performed in 57 patients (10.2%). Chemotherapy or radiotherapy was applied alone or in combination with other lines in 11 and 16 patients, respectively. RAI was applied in 552 (98.9%) patients. This information is reported as descriptive results only.</p></sec><sec><title>Survival</title><p>The 10-year OS rates were 97% and 89% for PTC and FTC, respectively, with a statistically significant difference (<italic>P</italic>=0.003) (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>). The 10-year DFS rates were 77.2% in PTC <italic>vs</italic>. 65% in FTC, without statistically significant difference (<italic>P</italic>=0.179).</p><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Kaplan-Meier plot of OS for PTC and FTC. OS, overall survival; PTC, papillary thyroid carcinoma; FTC, follicular thyroid carcinoma.</p></caption><graphic xlink:href="cbm-12-01-053-f1"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>PTC and FTC are generally indolent diseases and show good prognosis if treated appropriately. These DTCs are studied as a single group in investigative studies on the prognosis of thyroid carcinoma, in spite of their distinct biological behavior. Therefore, prognostic factors and prognosis of PTC and FTC patients should be analyzed independently<xref rid="r14" ref-type="bibr"><sup>14</sup></xref>. In the present study, we evaluated the factors that affected the prognosis of PTC and FTC in Egypt and compared them with other reports. Our results showed that the significant prognostic factors differed between the two types of DTC. However, some studies could not distinguish the PTC and FTC outcomes<xref rid="r10" ref-type="bibr"><sup>10</sup></xref><sup>-</sup><xref rid="r15" ref-type="bibr"><sup>15</sup></xref>, and other reports have considered a significantly poorer prognosis for FTC<xref rid="r16" ref-type="bibr"><sup>16</sup></xref><sup>,</sup><xref rid="r17" ref-type="bibr"><sup>17</sup></xref>, which is consistent with our report.</p><p>The age of PTC patients in our study ranged from 8 to 71 years old, with a median of 43 years old for PTC. By contrast, the age of FTC patients, ranged from 21 to 72 years old with a median of 43 years old. Other studies have reported an age range from 25 to 65 years old with the median age at diagnosis of 49 years old<xref rid="r15" ref-type="bibr"><sup>15</sup></xref>. These results agree with previous studies demonstrating that PTC and FTC can occur in children (accounting for 80% and 10%-20%, respectively)<xref rid="r16" ref-type="bibr"><sup>16</sup></xref>.</p><p>Female patients were more common than males in our study with a ratio of 2.28:1 in PTC and 2.5:1 for FTC, which agrees with the results of another report<xref rid="r15" ref-type="bibr"><sup>15</sup></xref>.</p><p>Ages older than 45 years old affected the OS and DFS of PTC patients on the univariate analysis. However, this factor was not an independent prognostic factor, contrary to previous results<xref rid="r18" ref-type="bibr"><sup>18</sup></xref>. Other studies have reported that its prognostic effect on DFS was weak<xref rid="r19" ref-type="bibr"><sup>19</sup></xref>. However, some studies have stated that ages 45 years old or older are a significant prognostic factor for FTC on univariate analysis (which is not consistent with our results), but are not an independent prognostic factor<xref rid="r20" ref-type="bibr"><sup>20</sup></xref>.</p><p>A previous study has demonstrated that gender only has a weak prognostic significance in DTC, with women showing better survival advantage than men. This result was attributed to a younger age distribution among women, and if age was also considered, gender would not exhibit prognostic significance<xref rid="r21" ref-type="bibr"><sup>21</sup></xref>. However, other studies have reported that male gender was an independent prognostic factor for PTC and FTC<xref rid="r18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="r22" ref-type="bibr"><sup>22</sup></xref>. By contrast, our study showed the sex of a patient had no effect on DFS and OS for both PTC and FTC. The difference in the results can be attributed to the difference in the numbers of cases.</p><p>In our study, multifocality had no effect on the OS of PTC and FTC patients. However, multifocality significantly influenced the DFS of PTC on the univariate analysis, but not on the multivariate analysis, which agrees with previous results<xref rid="r19" ref-type="bibr"><sup>19</sup></xref>. Passler <italic>et al</italic>. stated that multifocality significantly affects the outcome of both PTC and FTC patients<xref rid="r18" ref-type="bibr"><sup>18</sup></xref>. One study has reported that PTC with lymph node metastasis is more frequently detected in multiple than in solitary microcarcinomas and suggested that multiplicity reflects the aggressive behavior of PTC to some extent<xref rid="r23" ref-type="bibr"><sup>23</sup></xref>.</p><p>Tumor size of larger than 4 cm significantly affected OS and DFS of PTC patients, which is consistent with other studies<xref rid="r18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="r22" ref-type="bibr"><sup>22</sup></xref>. Therefore, careful and extensive surgery, as well as postoperative follow-up, is recommended for PTC tumor sizes larger than 4 cm even in the absence of other high-risk features. In FTC, the size of larger than 4 cm had marginal significance for DFS in FTC, but not for cause-specific survival (CSS) on multivariate analysis<xref rid="r20" ref-type="bibr"><sup>20</sup></xref>.</p><p>Lymph node metastasis was not an independent prognostic factor in our series, contrary to previous reports, which determined that this is an independent prognostic factor in PTC<xref rid="r18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="r19" ref-type="bibr"><sup>19</sup></xref>. Other studies have found that pathological node metastasis increases the rate of carcinoma recurrence<xref rid="r23" ref-type="bibr"><sup>23</sup></xref>.</p><p>We found that lymph node metastasis did not affect the outcome of FTC, which could be explained by the low possibility of FTC to metastasize to the regional lymph node, and lymph-node dissection is rarely performed during surgery for patients suspected of FTC. Thus, evaluating the prognostic value of this factor is important. Previous studies have found that FTC with pathological node metastasis show an aggressive pathology, e.g., widely invasive carcinoma, and extensive lymph-node dissection is recommended for these FTC cases<xref rid="r20" ref-type="bibr"><sup>20</sup></xref>. Passler <italic>et al</italic>.<xref rid="r18" ref-type="bibr"><sup>18</sup></xref> found that involvement of cervical lymph nodes is statistically significant in univariate analysis only in patients &#x0003e;45 years of age.</p><p>In our result and in those of other studies, the variant of PTC did not significantly affect survival<xref rid="r24" ref-type="bibr"><sup>24</sup></xref>. The tall cell variant has been reported to be typical with aggressive behavior and independently affects DFS and CSS of PTC patients, as shown by multivariate analysis<xref rid="r25" ref-type="bibr"><sup>25</sup></xref>. The difference in the results could be attributed to the very small number of this variant in our study.</p><p>The survival in H&#x000fc;rthle cell carcinoma was lower than the classic variant in the present study, but no statistical significance was found. Previous studies have found that most cases of oxyphilic cell variant were RAI refractory with worse prognosis than conventional FTC<xref rid="r18" ref-type="bibr"><sup>18</sup></xref>. Moreover, the prognosis of oxyphilic cell variant is reportedly similar to or even better than that of conventional FTC<xref rid="r20" ref-type="bibr"><sup>20</sup></xref>.</p><p>Similar to the reported results, the extrathyroid extension in our study was an independent prognostic factor for OS and DFS in PTC and DFS in FTC<xref rid="r18" ref-type="bibr"><sup>18</sup></xref><sup>,</sup><xref rid="r19" ref-type="bibr"><sup>19</sup></xref>. A rare event of extrathyroid extension in FTC had been reported and accounted for only 2% of patients and predicted an adverse prognosis<xref rid="r20" ref-type="bibr"><sup>20</sup></xref>.</p><p>The widely invasive FTC is more likely to recur and exhibit poorer prognosis than the minimally invasive FTC. Therefore, whether an FTC is widely or minimally invasive should be diagnosed during pathological examination to predict patient prognosis and select a subsequent therapy<xref rid="r20" ref-type="bibr"><sup>20</sup></xref>. In the present series, OS and DFS in widely invasive FTC were significantly lower than those of patients with minimally invasive FTC, which agrees with other studies. Thus, completion of total thyroidectomy followed by RAI ablation for widely invasive FTC patients is advised<xref rid="r18" ref-type="bibr"><sup>18</sup></xref>.</p><p>Although the incidence of DM in PTC is lower than that in FTC, PTC can metastasize not only to regional lymph nodes, but also to distant organs, such as the lung, bone, and brain. This study showed that the development of DM was an independent prognostic factor of PTC and FTC, as stated in previous reports<xref rid="r18" ref-type="bibr"><sup>18</sup></xref>. DM at surgery is one of the most important prognostic factors for CSS of patients<xref rid="r19" ref-type="bibr"><sup>19</sup></xref>.</p><p>Total or near-total thyroidectomy is primarily recommended to reduce the risk of recurrence, thereby improving survival<xref rid="r26" ref-type="bibr"><sup>26</sup></xref>. Bilimoria <italic>et al</italic>.<xref rid="r27" ref-type="bibr"><sup>27</sup></xref> demonstrated that total thyroidectomy results in lower recurrence rates and improves survival for PTC compared with lobectomy. However, less radical surgery for all low-risk patients is preferred in some studies<xref rid="r28" ref-type="bibr"><sup>28</sup></xref>.</p><p>Postoperative treatment consisted of radioactive <sup>131</sup>I (80-120 mCi) in patients who underwent at least a near-total thyroidectomy and thyroxin suppression therapy. This treatment was used to ablate residual normal thyroid tissue and adjuvant therapy of subclinically or clinically apparent residual disease. Several studies have suggested a 50% 10-year reduction in recurrence risk and decrease in mortality rate and risk of metastasis<xref rid="r29" ref-type="bibr"><sup>29</sup></xref><sup>,</sup><xref rid="r30" ref-type="bibr"><sup>30</sup></xref>. Chemotherapy was used in some cases of metastatic, non-resectable, or iodine non-responder-differentiated thyroid cancer. However, this modality may result in rare complete remission and uncommon long-term responses<xref rid="r30" ref-type="bibr"><sup>30</sup></xref>. Several single chemotherapeutic agents are used in thyroid cancer. Additionally, this treatment has no benefit when used in combination therapy to improve the overall response, but may instead increase toxicity<xref rid="r30" ref-type="bibr"><sup>30</sup></xref>.</p><p>In conclusion, the significant prognostic factors differ between the two types of DTC. Therefore, PTC and FTC patients should be analyzed and reported independently.</p><p>PTC prognosis is widely and significantly affected by the age and extrathyroid extension compared with FTC. Additionally, survival of FTC patients is significantly poorer than that of PTC patients.</p></sec></body><back><fn-group><fn fn-type="conflict"><p>No potential conflicts of interest are disclosed.</p></fn></fn-group><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacini</surname><given-names>F</given-names></name><name><surname>Schlumberger</surname><given-names>M</given-names></name><name><surname>Dralle</surname><given-names>H</given-names></name><name><surname>Elisei</surname><given-names>R</given-names></name><name><surname>Smit</surname><given-names>JW</given-names></name><name><surname>Wiersinga</surname><given-names>W</given-names></name><etal/></person-group><article-title>European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium.</article-title><source>Eur J Endocrinol</source><year>2006</year>;<volume>154</volume>:<fpage>787</fpage>-<lpage>803</lpage>.<pub-id pub-id-type="pmid">16728537</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="book">Hu MI, Vassilopoulou-Sellin R, Lustig R, Lamont JP. Thyroid and Parathyroid Cancers. In: Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ. eds. Cancer Management: A Multidisciplinary Approach. 11 eds. Manhasset, NY: CMP Medica, 2008.</mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawka</surname><given-names>AM</given-names></name><name><surname>Thephamongkhol</surname><given-names>K</given-names></name><name><surname>Brouwers</surname><given-names>M</given-names></name><name><surname>Thabane</surname><given-names>L</given-names></name><name><surname>Browman</surname><given-names>G</given-names></name><name><surname>Gerstein</surname><given-names>HC</given-names></name></person-group>. <article-title>Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer.</article-title><source>J Clin Endocrinol Metab</source><year>2004</year>;<volume>89</volume>:<fpage>3668</fpage>-<lpage>3676</lpage>.<pub-id pub-id-type="pmid">15292285</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="book">Livolsi VA, Albores-Saavedra J, Asa SL. Papillary carcinoma. In: DeLellis RA, Lloyd R, LiVolsi VA, Eng C. eds. Pathology and Genetics of Tumors of the Endocrine Organs. World Health Organization Classification of Tumors. Lyon: IARC Press, 2004:57-66.</mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volante</surname><given-names>M</given-names></name><name><surname>Landolfi</surname><given-names>S</given-names></name><name><surname>Chiusa</surname><given-names>L</given-names></name><name><surname>Palestini</surname><given-names>N</given-names></name><name><surname>Motta</surname><given-names>M</given-names></name><name><surname>Codegone</surname><given-names>A</given-names></name><etal/></person-group><article-title>Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients.</article-title><source>Cancer</source><year>2004</year>;<volume>100</volume>:<fpage>950</fpage>-<lpage>957</lpage>.<pub-id pub-id-type="pmid">14983490</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Regalbuto</surname><given-names>C</given-names></name><name><surname>Malandrino</surname><given-names>P</given-names></name><name><surname>Tumminia</surname><given-names>A</given-names></name><name><surname>Le Moli</surname><given-names>R</given-names></name><name><surname>Vigneri</surname><given-names>R</given-names></name><name><surname>Pezzino</surname><given-names>V.</given-names></name></person-group><article-title>A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases.</article-title><source>Thyroid</source><year>2011</year>;<volume>21</volume>:<fpage>383</fpage>-<lpage>389</lpage>.<pub-id pub-id-type="pmid">21309722</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>CE</given-names></name><name><surname>Owen</surname><given-names>RP</given-names></name><name><surname>Rodrigo</surname><given-names>JP</given-names></name><name><surname>Rinaldo</surname><given-names>A</given-names></name><name><surname>Devaney</surname><given-names>KO</given-names></name><name><surname>Ferlito</surname><given-names>A</given-names></name></person-group>. <article-title>Aggressive variants of papillary thyroid carcinoma.</article-title><source>Head Neck</source><year>2011</year>;<volume>33</volume>:<fpage>1052</fpage>-<lpage>1059</lpage>.<pub-id pub-id-type="pmid">20824810</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>CY</given-names></name><name><surname>Chan</surname><given-names>WF</given-names></name><name><surname>Lam</surname><given-names>KY</given-names></name><name><surname>Wan</surname><given-names>KY</given-names></name></person-group>. <article-title>Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival.</article-title><source>Ann Surg</source><year>2005</year>;<volume>242</volume>:<fpage>708</fpage>-<lpage>715</lpage>.<pub-id pub-id-type="pmid">16244545</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Avanzo</surname><given-names>A</given-names></name><name><surname>Treseler</surname><given-names>P</given-names></name><name><surname>Ituarte</surname><given-names>PH</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Streja</surname><given-names>L</given-names></name><name><surname>Greenspan</surname><given-names>FS</given-names></name><etal/></person-group><article-title>Follicular thyroid carcinoma: histology and prognosis.</article-title><source>Cancer</source><year>2004</year>;<volume>100</volume>:<fpage>1123</fpage>-<lpage>1129</lpage>.<pub-id pub-id-type="pmid">15022277</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cushing</surname><given-names>SL</given-names></name><name><surname>Palme</surname><given-names>CE</given-names></name><name><surname>Audet</surname><given-names>N</given-names></name><name><surname>Eski</surname><given-names>S</given-names></name><name><surname>Walfish</surname><given-names>PG</given-names></name><name><surname>Freeman</surname><given-names>JL</given-names></name></person-group>. <article-title>Prognostic factors in well-differentiated thyroid carcinoma.</article-title><source>Laryngoscope</source><year>2004</year>;<volume>114</volume>:<fpage>2110</fpage>-<lpage>2115</lpage>.<pub-id pub-id-type="pmid">15564829</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hundahl</surname><given-names>SA</given-names></name><name><surname>Fleming</surname><given-names>ID</given-names></name><name><surname>Fremgen</surname><given-names>AM</given-names></name><name><surname>Menck</surname><given-names>HR</given-names></name></person-group>. <article-title>A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995</article-title><comment>[see commetns]</comment>. <source>Cancer</source><year>1998</year>;<volume>83</volume>:<fpage>2638</fpage>-<lpage>2648</lpage>.<pub-id pub-id-type="pmid">9874472</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carter</surname><given-names>WB</given-names></name><name><surname>Tourtelot</surname><given-names>JB</given-names></name><name><surname>Savell</surname><given-names>JG</given-names></name><name><surname>Lilienfeld</surname><given-names>H</given-names></name></person-group>. <article-title>New treatments and shifting paradigms in differentiated thyroid cancer management.</article-title><source>Cancer Control</source><year>2011</year>;<volume>18</volume>:<fpage>96</fpage>-<lpage>103</lpage>.<pub-id pub-id-type="pmid">21451452</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="book">Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. eds. AJCC Cancer Staging Manual. 7thed. New York(NY): Springer; 2012.</mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="other">Ito Y, Miyauchi A. Prognostic factors of papillary and follicular carcinomas in Japan based on data of kuma hospital. J Thyroid Res 2012;2012:973497.</mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="web">Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD: <ext-link ext-link-type="uri" xlink:href="http://seer.cancer.gov/csr/1975_2007/">http://seer.cancer.gov/csr/1975_2007/</ext-link>, based on November 2009 SEER data submission, posted to the SEER web site; 2010.</mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>D.</given-names></name></person-group><article-title>Radiation carcinogenesis: lessons from Chernobyl.</article-title><source>Oncogene</source><year>2008</year>;<volume>27</volume><issue>Suppl 2</issue>:<fpage>S9</fpage>-<lpage>18</lpage>.<pub-id pub-id-type="pmid">19956182</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>GG</given-names></name><name><surname>Vlantis</surname><given-names>AC</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>van Hasselt</surname><given-names>CA</given-names></name></person-group>. <article-title>Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer.</article-title><source>Curr Cancer Drug Targets</source><year>2008</year>;<volume>8</volume>:<fpage>367</fpage>-<lpage>377</lpage>.<pub-id pub-id-type="pmid">18690843</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passler</surname><given-names>C</given-names></name><name><surname>Scheuba</surname><given-names>C</given-names></name><name><surname>Prager</surname><given-names>G</given-names></name><name><surname>Kaczirek</surname><given-names>K</given-names></name><name><surname>Kaserer</surname><given-names>K</given-names></name><name><surname>Zettinig</surname><given-names>G</given-names></name><etal/></person-group><article-title>Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region.</article-title><source>Endocr Relat Cancer</source><year>2004</year>;<volume>11</volume>:<fpage>131</fpage>-<lpage>139</lpage>.<pub-id pub-id-type="pmid">15027890</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Ichihara</surname><given-names>K</given-names></name><name><surname>Masuoka</surname><given-names>H</given-names></name><name><surname>Fukushima</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Kihara</surname><given-names>M</given-names></name><etal/></person-group><article-title>Establishment of an intraoperative staging system (iStage) by improving UICC TNM classification system for papillary thyroid carcinoma.</article-title><source>World J Surg</source><year>2010</year>;<volume>34</volume>:<fpage>2570</fpage>-<lpage>2580</lpage>.<pub-id pub-id-type="pmid">20625728</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>It</surname><given-names>Y</given-names></name><name><surname>Hirokawa</surname><given-names>M</given-names></name><name><surname>Higashiyama</surname><given-names>T</given-names></name><name><surname>Takamura</surname><given-names>Y</given-names></name><name><surname>Miya</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Prognosis and prognostic factors of follicular carcinoma in Japan: importance of postoperative pathological examination.</article-title><source>World J Surg</source><year>2007</year>;<volume>31</volume>:<fpage>1417</fpage>-<lpage>1424</lpage>.<pub-id pub-id-type="pmid">17534542</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuriakose</surname><given-names>MA</given-names></name><name><surname>Hicks</surname><given-names>WL</given-names><suffix>Jr</suffix></name><name><surname>Loree</surname><given-names>TR</given-names></name><name><surname>Yee</surname><given-names>H</given-names></name></person-group>. <article-title>Risk group-based management of differentiated thyroid carcinoma.</article-title><source>J R Coll Surg Edinb</source><year>2001</year>;<volume>46</volume>:<fpage>216</fpage>-<lpage>223</lpage>.<pub-id pub-id-type="pmid">11523714</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Miyauchi</surname><given-names>A.</given-names></name></person-group><article-title>Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid.</article-title><source>Endocr J</source><year>2009</year>;<volume>56</volume>:<fpage>177</fpage>-<lpage>192</lpage>.<pub-id pub-id-type="pmid">18703852</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Tomoda</surname><given-names>C</given-names></name><name><surname>Uruno</surname><given-names>T</given-names></name><name><surname>Takamura</surname><given-names>Y</given-names></name><name><surname>Miya</surname><given-names>A</given-names></name><name><surname>Kobayashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Papillary microcarcinoma of the thyroid: how should it be treated?</article-title><source>World J Surg</source><year>2004</year>;<volume>28</volume>:<fpage>1115</fpage>-<lpage>1121</lpage>.<pub-id pub-id-type="pmid">15490053</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagag</surname><given-names>P</given-names></name><name><surname>Hod</surname><given-names>N</given-names></name><name><surname>Kummer</surname><given-names>E</given-names></name><name><surname>Cohenpour</surname><given-names>M</given-names></name><name><surname>Horne</surname><given-names>T</given-names></name><name><surname>Weiss</surname><given-names>M.</given-names></name></person-group><article-title>Follicular variant of papillary thyroid carcinoma: clinical-pathological characterization and long-term follow-up.</article-title><source>Cancer J</source><year>2006</year>;<volume>12</volume>:<fpage>275</fpage>-<lpage>282</lpage>.<pub-id pub-id-type="pmid">16925971</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Hirokawa</surname><given-names>M</given-names></name><name><surname>Fukushima</surname><given-names>M</given-names></name><name><surname>Inoue</surname><given-names>H</given-names></name><name><surname>Yabuta</surname><given-names>T</given-names></name><name><surname>Uruno</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prevalence and prognostic significance of poor differentiation and tall cell variant in papillary carcinoma in Japan.</article-title><source>World J Surg</source><year>2008</year>;<volume>32</volume>:<fpage>1535</fpage>-<lpage>1543</lpage>; <lpage>discussion 1544-1545</lpage>.<pub-id pub-id-type="pmid">18224467</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duren</surname><given-names>M</given-names></name><name><surname>Yavuz</surname><given-names>N</given-names></name><name><surname>Bukey</surname><given-names>Y</given-names></name><name><surname>Ozyegin</surname><given-names>MA</given-names></name><name><surname>Gundogdu</surname><given-names>S</given-names></name><name><surname>A&#x000e7;bay</surname><given-names>O</given-names></name><etal/></person-group><article-title>Impact of initial surgical treatment on survival of patients with differentiated thyroid cancer: experience of an endocrine surgery center in an iodine-deficient region.</article-title><source>World J Surg</source><year>2000</year>;<volume>24</volume>:<fpage>1290</fpage>-<lpage>1294</lpage>.<pub-id pub-id-type="pmid">11038196</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilimoria</surname><given-names>KY</given-names></name><name><surname>Bentrem</surname><given-names>DJ</given-names></name><name><surname>Ko</surname><given-names>CY</given-names></name><name><surname>Stewart</surname><given-names>AK</given-names></name><name><surname>Winchester</surname><given-names>DP</given-names></name><name><surname>Talamonti</surname><given-names>MS</given-names></name><etal/></person-group><article-title>Extent of surgery affects survival for papillary thyroid cancer.</article-title><source>Ann Surg</source><year>2007</year>;<volume>246</volume>:<fpage>375</fpage>-<lpage>381</lpage>; <lpage>discussion 381-384</lpage>.<pub-id pub-id-type="pmid">17717441</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Udelsman</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name></person-group><article-title>The current management of thyroid cancer.</article-title><source>Adv Surg</source><year>1999</year>;<volume>33</volume>:<fpage>1</fpage>-<lpage>27</lpage>.<pub-id pub-id-type="pmid">10572560</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzaferri</surname><given-names>EL</given-names></name><name><surname>Jhiang</surname><given-names>SM</given-names></name></person-group>. <article-title>Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.</article-title><source>Am J Med</source><year>1994</year>;<volume>97</volume>:<fpage>418</fpage>-<lpage>428</lpage>.<pub-id pub-id-type="pmid">7977430</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname><given-names>JA</given-names></name><name><surname>Hill</surname><given-names>CS</given-names><suffix>Jr</suffix></name></person-group>. <article-title>Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients.</article-title><source>N Engl J Med</source><year>1974</year>;<volume>290</volume>:<fpage>193</fpage>-<lpage>197</lpage>.<pub-id pub-id-type="pmid">4808917</pub-id></mixed-citation></ref></ref-list></back></article>